Modern drug discovery has evolved from serendipitous observation into atomic-scale molecular engineering, driven by the convergence of high-resolution structural biology, Artificial Intelligence (AI), and Quantum Computing (QC). This transition aims to reduce the high attrition rates and costs of traditional methods by predicting efficacy and toxicity in silico before physical testing.

Artificial Intelligence and AlphaFold AI has graduated from a buzzword to a platform-scale engine. AlphaFold 3 represents a paradigm shift, moving beyond static protein folding to accurately predicting the joint structures of complexes involving proteins, ligands, nucleic acids, and antibodies. This capability accelerates Structure-Based Drug Design (SBDD) by identifying binding pock ...